VIDAI published a research paper titled Non-Invasive Prediction of Embryo Ploidy Status Using Metabolomic Profiling and Machine Learning.
Published
Signal category
Research & Knowledge
Quote
“our work has been published: "Non-Invasive Prediction of Embryo Ploidy Status Using Metabolomic Profiling and Machine Learning."”
— Nabil A.|VIDAI team
Company
VIDAI
Predict. Personalize. Perform | The Future of Fertility software is Here.
- Industry
- Software Development
- Location
- San Diego, US
- Company size
- 41 employees
Smart Solutions for Successful Conceptions... VIDAI is an innovative and AI- Powered EMR solution, is fully acquired by Progenesis INC, USA and is the first company in US to introduce Next Generation Sequencing (NGS) for Preimplantation Genetic Testing for Aneuploidy (PGT-A) and Preimplantation Genetic Testing for Monogenic disorders (PGT-M). With this acquisition we opens up new opportunities for us to elevate our offerings and bring even more value to your projects. VIDAI is a advanced Operating System tailored specifically for fertility clinics. With a bold vision to transform the healthcare industry, VIDAI harnesses the immense potential of AI and automation. Its state-of-the-art Software-as-a-Service (SaaS) offering represents a pinnacle of technological advancement, seamlessly optimizing clinic operations, elevating data management practices, and ultimately enhancing both patient outcomes and overall clinic performance. By streamlining processes and leveraging cutting-edge capabilities.